EGFR exon 19 deletion

TROP-LUNG: A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy (clinicaltrials.gov)

A Prospective, Non-interventional, Real-World Study on Patient-Reported Outcomes of Third-Generation EGFR-TKIs Combined with Radiotherapy for Advanced NSCLC Patients with EGFR Mutations (ChiCTR2600121548)

Zorifertinib Plus Radiotherapy as First-Line Treatment in EGFR-Mutant NSCLC with Brain Metastases: A Prospective Clinical Study (ChiCTR2600121513)

Aumolertinib with or without Radiotherapy for Treatment-Naïve EGFR-Mutated Oligometastatic Non-Small Cell Lung Cancer: A Phase III, Multicenter, Open-Label, Randomized Controlled Trial (ChiCTR2600121546)

Almonertinib Plus Oral Vinorelbine as First-line Treatment for EGFR-sensitive Mutation-positive Advanced Non-small Cell Lung Cancer with Performance Status 2-4: A Prospective, Multicenter, Single-arm, Phase II Clinical Study (ChiCTR2600121540)

A Real-World Study Evaluating the Efficacy and Safety of Zorifertinib in Patients with NSCLC and Leptomeningeal Metastases after Resistance to Third-Generation EGFR-TKIs: A Bidirectional, Non-Interventional, Observational, Multicenter Study (ChiCTR2600121192)

ctDNA-guided dynamic monitoring for befotertinib combined with radiotherapy in oligometastatic non-small cell lung cancer with EGFR mutations: a single-arm, multicenter, exploratory study (ChiCTR2600120895)

Pivotal study to evaluate YL202 versus Docetaxel in Patients with Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer (ChiCTR2600120457)

Study on the incidence of venous thromboembolism in patients with locally advanced or metastatic NSCLC harboring EGFR-sensitive mutations treated with befotertinib with or without rivaroxaban (ChiCTR2600119885)

Development and Application of a Novel Method for Therapeutic Drug Monitoring of Furmonertinib (ChiCTR2600119489)

MARIPOSA-2: A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (clinicaltrials.gov)

An IIT, open-label, multi-arm, prospective clinical study to investigate the efficacy and safety of toripalimab combined with furmonertinib in non-small cell lung cancer patients with EGFR sensitive mutations and PD-L1 >= 1% of first-line treatment (ChiCTR2300076542)